TY - JOUR
T1 - Impact of second-line and later cetuximab-containing therapy and KRAS genotypes in patients with metastatic colorectal cancer
T2 - A multicenter study in Japan
AU - Saeki, Hiroshi
AU - Emi, Yasunori
AU - Kumashiro, Ryuichi
AU - otsu, hajime
AU - Kawano, Hiroyuki
AU - Ando, Koji
AU - Ida, Satoshi
AU - Kimura, Yasue
AU - Tokunaga, Eriko
AU - Oki, Eiji
AU - Morita, Masaru
AU - Shimokawa, Mototsugu
AU - Maehara, Yoshihiko
N1 - Funding Information:
This study was supported by the Kyushu Study Group of Clinical Cancer (KSCC0904). We thank Akio Nagaoka for assisting in the preparation of the manuscript.
PY - 2014/8
Y1 - 2014/8
N2 - Purposes: This retrospective study evaluated the treatment outcomes and clinical relevance of the KRAS mutation status in Japanese metastatic colorectal cancer patients treated with second-line and later cetuximab-containing therapy. Methods: The subjects comprised 65 patients with metastatic colorectal cancer who received cetuximab-containing therapy. At the start of cetuximab-containing therapy, the KRAS mutation status had been proven to be wild type in 12 patients. Tumors were retrospectively screened for KRAS mutations using direct sequencing. Results: A detailed analysis revealed the presence of 24 wild-type (57.1 %) and 18 mutant tumors (42.9 %). Grade 3-4 neutropenia and anemia were observed in 21 (32.3 %) and nine (13.8 %) patients, respectively. An acne-like rash was observed in 50 patients (76.9 %), and among them three patients (4.6 %) experienced a Grade 3 rash. A KRAS mutation was associated with resistance to cetuximab-containing treatment (11.1 vs. 41.7 % responders among 18 mutant and 36 wild-type patients, respectively; P = 0.03). A KRAS mutation was also associated with poorer survival (MST: 6.9 vs. 14.1 months in 18 mutant and 36 wild-type patients, respectively; P = 0.018). Conclusions: The present results indicated the clinical relevance of KRAS mutations in predicting the efficacy of cetuximab-containing therapy for metastatic colorectal patients in the Japanese population.
AB - Purposes: This retrospective study evaluated the treatment outcomes and clinical relevance of the KRAS mutation status in Japanese metastatic colorectal cancer patients treated with second-line and later cetuximab-containing therapy. Methods: The subjects comprised 65 patients with metastatic colorectal cancer who received cetuximab-containing therapy. At the start of cetuximab-containing therapy, the KRAS mutation status had been proven to be wild type in 12 patients. Tumors were retrospectively screened for KRAS mutations using direct sequencing. Results: A detailed analysis revealed the presence of 24 wild-type (57.1 %) and 18 mutant tumors (42.9 %). Grade 3-4 neutropenia and anemia were observed in 21 (32.3 %) and nine (13.8 %) patients, respectively. An acne-like rash was observed in 50 patients (76.9 %), and among them three patients (4.6 %) experienced a Grade 3 rash. A KRAS mutation was associated with resistance to cetuximab-containing treatment (11.1 vs. 41.7 % responders among 18 mutant and 36 wild-type patients, respectively; P = 0.03). A KRAS mutation was also associated with poorer survival (MST: 6.9 vs. 14.1 months in 18 mutant and 36 wild-type patients, respectively; P = 0.018). Conclusions: The present results indicated the clinical relevance of KRAS mutations in predicting the efficacy of cetuximab-containing therapy for metastatic colorectal patients in the Japanese population.
UR - http://www.scopus.com/inward/record.url?scp=84904390630&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904390630&partnerID=8YFLogxK
U2 - 10.1007/s00595-013-0716-0
DO - 10.1007/s00595-013-0716-0
M3 - Article
C2 - 24013837
AN - SCOPUS:84904390630
VL - 44
SP - 1457
EP - 1464
JO - Surgery Today
JF - Surgery Today
SN - 0941-1291
IS - 8
ER -